Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Ledoux

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Chest|July 7, 2023
Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 CasesAnne Coste, Anne Conrad, Raphaël Porcher, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2026
A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trialsAnne Coste, Olivier Paccoud, François Danion, et al.
American Journal of Hematology|January 8, 2026
Real-World Effectiveness and Safety of Fostamatinib in Difficult-to-Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in FranceGuillaume Moulis, Matthieu Mahévas, Jean-François Viallard, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 4, 2021
Factors associated with coinfections in invasive aspergillosis: a retrospective cohort studyFrançois Danion, Céline Duval, François Séverac, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2025
Epidemiology and Prognostic Factors Associated With Mold-Positive Blood Cultures: 10-Year Data From a French Prospective Surveillance Program (2012-2022)Thiziri Tala-Ighil, Dea Garcia-Hermoso, Frédéric Dalle, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood Advances|May 2, 2022
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA surveySylvain Lamure, Jon Salmanton-García, Elena Robin-Marieton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO TrialUwe Platzbecker, Lionel Adès, Pau Montesinos, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Chest|July 7, 2023
Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 CasesAnne Coste, Anne Conrad, Raphaël Porcher, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2026
A step toward defining optimal liposomal amphotericin B treatment duration in pulmonary mucormycosis: results from emulated trialsAnne Coste, Olivier Paccoud, François Danion, et al.
American Journal of Hematology|January 8, 2026
Real-World Effectiveness and Safety of Fostamatinib in Difficult-to-Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in FranceGuillaume Moulis, Matthieu Mahévas, Jean-François Viallard, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 4, 2021
Factors associated with coinfections in invasive aspergillosis: a retrospective cohort studyFrançois Danion, Céline Duval, François Séverac, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 10, 2025
Epidemiology and Prognostic Factors Associated With Mold-Positive Blood Cultures: 10-Year Data From a French Prospective Surveillance Program (2012-2022)Thiziri Tala-Ighil, Dea Garcia-Hermoso, Frédéric Dalle, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood Advances|May 2, 2022
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA surveySylvain Lamure, Jon Salmanton-García, Elena Robin-Marieton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO TrialUwe Platzbecker, Lionel Adès, Pau Montesinos, et al.
Therapeutic Advances in Hematology|March 16, 2023
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registryMonia Marchetti, Jon Salmanton-García, Shaimaa El-Ashwah, et al.
Frontiers in Oncology|October 24, 2022
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)Maria Stefania Infante, Jon Salmanton-García, Ana Fernández-Cruz, et al.
Pageof 5